| |
| |
|
| Insider
Information: |
Smith Sandford D |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
386,982 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,133,045 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
386,982 |
|
|
| Total
Value |
$1,133,045 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
7
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -24.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
Director |
2007-06-20 |
131,205 |
2004-01-15 |
0 |
Premium* |
|
|
Genzyme Corp |
GENZ |
Exe VP,President Intl ... |
2011-04-04 |
0 |
2005-07-29 |
0 |
Premium* |
|
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
Director |
2016-11-29 |
0 |
2013-08-09 |
0 |
Premium* |
|
|
Palisade Bio Inc |
PALI |
Director |
2019-07-01 |
219,916 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2017-01-05 |
16,160 |
2014-10-22 |
0 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-01-27 |
900 |
2016-11-29 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-01-02 |
18,801 |
2020-06-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
113 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2004-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
0 |
|
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2005-07-29 |
4 |
S |
$74.64 |
$42,396 |
I/I |
(568) |
0 |
|
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2011-04-04 |
4 |
D |
$74.00 |
$1,529,654 |
D/D |
(20,671) |
0 |
0 |
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
Director |
– • – |
2013-08-12 |
4 |
S |
$92.25 |
$141,791 |
D/D |
(1,537) |
0 |
0 |
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
Director |
– • – |
2013-10-29 |
4 |
AS |
$95.00 |
$237,690 |
D/D |
(2,502) |
0 |
0 |
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
Director |
– • – |
2016-11-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,890) |
0 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-12 |
4 |
S |
$20.77 |
$313,907 |
D/D |
(15,045) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-15 |
4 |
S |
$22.00 |
$146,652 |
D/D |
(6,666) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-17 |
4 |
S |
$23.00 |
$158,861 |
D/D |
(6,907) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-22 |
4 |
S |
$24.00 |
$245,000 |
D/D |
(10,000) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-07 |
4 |
AS |
$26.00 |
$310,524 |
D/D |
(11,742) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-08 |
4 |
AS |
$27.00 |
$38,718 |
D/D |
(1,434) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-15 |
4 |
AS |
$29.00 |
$193,343 |
D/D |
(6,667) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-10-05 |
4 |
AS |
$30.00 |
$178,080 |
D/D |
(5,936) |
0 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-01-04 |
4 |
A |
$19.56 |
$9,995 |
D/D |
511 |
511 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2005-07-18 |
4 |
S |
$68.79 |
$37,835 |
I/I |
(550) |
568 |
|
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2017-01-27 |
4 |
D |
$9.38 |
$1,388 |
D/D |
(148) |
900 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-09 |
4 |
AS |
$23.79 |
$659,990 |
D/D |
(27,582) |
920 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-15 |
4 |
AS |
$25.00 |
$270,350 |
D/D |
(10,714) |
920 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-23 |
4 |
AS |
$26.50 |
$132,500 |
D/D |
(5,000) |
920 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-26 |
4 |
AS |
$27.00 |
$135,000 |
D/D |
(5,000) |
920 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-27 |
4 |
AS |
$27.50 |
$270,323 |
D/D |
(9,739) |
920 |
0 |
% |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2017-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
456 |
1,048 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice PresidentOfficer |
• – – |
2005-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,118 |
|
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-08 |
4 |
OE |
$6.21 |
$8,905 |
D/D |
1,434 |
1,434 |
0 |
- |
|
113 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
